



PANEL SESSION 3 – Tuesday June 9, 2026 | 1pm – 2pm

[PN17 – AI Transforming Evidence Generation For HTA](#)

Contributors: Karen Facey, Stephen Duffield, Jing Wang-Silvanto, Andrew Spiegel

Summary: All stakeholders are recognising the value AI can bring to evidence generation, from extraction of data from unstructured clinical records to creation of synthetic real-world data. However, as adoption increases, issues of governance, validation and interpretation must be addressed. The human must be kept in the loop and we need to keep learning about optimal use of AI.

[PN18 – Equity In HTA: Regional Experiences And Approaches To Measuring Impact](#)

Contributors: Luciene Bonan, Santiago Hasdeu, Hugh McGuire, Alexandre Lemgruber

Summary: This panel invites participants to reconsider equity as a core pillar of Health Technology Assessment (HTA) - not only as an ethical value but as a technical element essential for reducing inequalities and enhancing the social impact of health decisions. Drawing on experiences from Brazil, Argentina, and United Kingdom, it explores methods, progress, and challenges toward fairer, more sustainable systems.

[PN19 – From Data To Decisions: Strengthening HTA Literacy And Statistical Capacity For Future-Ready Health Systems](#)

Contributors: Debjani Mueller, Abhirup Dutta Majumdar, Hiya Banerjee, Antonio Remiro- Azócar

Summary: The changing HTA landscape is transforming the role of statisticians, demanding new competencies to navigate a complex regulatory environment. The current framework does not differentiate competencies of various professional groups, including statisticians. This panel highlights the need for interdisciplinary training, regulatory competency, and enhanced communication skills to enable context-sensitive, future oriented, and trustworthy assessments.

[PN20 – Improving Patient Involvement In Health Technology Assessments From Goal Setting To Evaluation](#)

Contributors: Veronica Lopez Gousset, Daniel Ollendorf, Daniel Cairns, Anke-Peggy Holtorf

Summary: Goal setting and evaluation of patient involvement in health technology assessments (HTA) are closely interconnected but rarely studied, planned for, or implemented together. This panel will integrate theory and practice from conception to evaluation, address implementation challenges, capacity constraints, and buy-in barriers, and share learnings to encourage a lifecycle approach to patient involvement in HTA.



[PN21 – Interventions To Reach Zero-Dose Children In Sub-Saharan Africa: What Works And What Doesn't—Experiences From Kenya, Nigeria, And Rwanda](#)

Contributors: Felix Rubuga Kitema, Namu Kimunguyi, Taiwo Adebesein, Hassan Sibomana

Summary: How do immunisation programs close zero-dose gaps in practice? Three country cases—Kenya, Nigeria, Rwanda—examine identification, delivery, and monitoring with real implementation lessons. Content includes Big Catch-Up, ZDROP, community engagement, data visibility, defaulter tracing, and integrated outreach using DHIS2/eCHIS. The session emphasises transferable actions, disciplined execution, and a brief Q&A.

[PN22 – The Role Of HTA In The Current Era](#)

Contributors: Martin Price, Nicole Mittmann, Alric Ruether, Ann Single

Summary: We are in a dynamic time, with shifting geopolitical and fiscal pressures shaping governments, health systems, and nations. In this context, what is the role and value of HTA? How can HTA processes add value as pricing approaches shift? What will the fit-for-purpose HTA system of the future encompass?

[PN23 – Beyond the Health System: Should the Societal Perspective Be Included in HTA?](#)

Contributors: Julie Van Bavel, Yvette Venable, Chris Munoz, Thanthima (Net) Suwanthawornkul

Summary: The societal perspective in health is an approach to economic evaluation that considers all costs and benefits of a health intervention, regardless of who experiences them. Capturing the full value of health technologies using a broader, more flexible value framework may improve transparency in healthcare decision-making and inform equitable funding decisions. Whilst we all agree that aligning the perspective of an economic evaluation with a health system's goals and societal values may more accurately determine the value of new health technologies, how do we capture this in HTA?

[PN24 – Values, Outcomes And Impact Of Health Technology Assessment Agencies: System Shapers For Resilient, Inclusive And Future-Ready Health Systems](#)

Contributors: Manuel Donato, Iñaki Gutierrez Ibarluzea, Vania Canuto, Fatima Salih

Summary: This panel presents the findings and vision of a multidisciplinary systematic review on how HTA agencies serve as system shapers in health. It highlights their crucial role in strengthening resilience, equity and innovation by linking evidence to decision-making and policy. The session will offer practical guidance for health system transformation, supporting effective and sustainable stewardship for inclusive systems.